LCID
Lucid Group, Inc.
LCID lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
VENU
Venu Holding Corporation
There isn't enough reported data to score VENU yet.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
VENU Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
VENU's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
VENU PE Valuation
VENU has no meaningful PE right now: it lost money over the past year.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
VENU Forward outlook
There aren't enough analyst estimates for VENU to show an outlook.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID has the edge over VENU in the latest year-over-year earnings comparison.
VENU Earnings Per Share
VENU lost $0.91 per share over the past year, a bigger loss than the year before.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over VENU on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID has the edge over VENU on profitability, with a higher operating margin.
VENU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $4.8M | +6.9% |
| Q1 2026 | $3.9M | +11% |
| Q4 2025 | $4.5M | +6.1% |
| Q3 2025 | $5.4M | -1.2% |
| Q2 2025 | $4.5M | +7.5% |
| Q1 2025 | $3.5M | -11% |
| Q4 2024 | $4.3M | +9.1% |
| Q3 2024 | $5.5M | +39% |
VENU's revenue is growing: $5M last quarter, up 6.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -320% | -90 points |
| Q1 2026 | -294% | +235 points |
| Q4 2025 | -162% | -12 points |
| Q3 2025 | -185% | -118 points |
| Q2 2025 | -230% | -126 points |
| Q1 2025 | -530% | -201 points |
| Q4 2024 | -150% | -73 points |
| Q3 2024 | -67% | +3 points |
VENU's operating margin was −320% last quarter, down 90 points from the same quarter a year ago.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
VENU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$67.9M | -$50.3M |
| Q1 2026 | -$74.4M | -$43.3M |
| Q4 2025 | -$52.4M | -$31.9M |
| Q2 2025 | -$17.6M | -$4.1M |
| Q1 2025 | -$31.1M | -$19.4M |
| Q4 2024 | -$20.4M | -$10.1M |
VENU has burned cash in almost every quarter: −$228M over the past year, against −$83M the year before.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has the edge over VENU on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
VENU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +12.4M shares |
| 1 year | +59% | +22M shares |
VENU has 59M diluted shares, up 59% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
VENU Net Leverage
VENU's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
VENU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.1 | Oversold |
| Stochastic | 15.7 | Oversold |
VENU's weekly RSI is 27 (oversold) and its Stochastic is 16 (oversold).
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
VENU PE vs Consumer Cyclical Sector
VENU has no meaningful PE right now: it lost money over the past year.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
VENU has stronger trend alignment. LCID is above 0 of 5 weekly averages versus VENU above 0 of 4.
VENU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.32 | 5.3% below |
| 20 week MA | $1.76 | 29% below |
| 50 week MA | $3.95 | 68% below |
| 100 week MA | $7.49 | 83% below |
VENU is in a downtrend: it's below all four of its weekly moving averages, and 83% below its 100-week average.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has the edge over VENU on returns for 2026, with the stronger performance.
VENU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $10.8 | $9.74 | -9.8% |
| 2025 | $9.74 | $8.17 | -16% |
| 2026 YTD | $8.17 | $1.25 | -85% |
VENU has finished every year since 2024 lower, and it's down 85% so far in 2026.